文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

治疗性高温与无发热脓毒症重症患者生存改善相关:一项先导随机试验

Therapeutic Hyperthermia Is Associated With Improved Survival in Afebrile Critically Ill Patients With Sepsis: A Pilot Randomized Trial.
PubMed 文献 · Crit Care Med · 2022-02-07
一句话结论对无发热脓毒症机械通气患者行强制空气加温48小时,28天死亡率18% vs 43%(绝对风险降低25%,95%CI 2-48%),但免疫指标无差异。

单中心、前瞻性、开放标签随机对照先导试验,纳入56例机械通气的无发热脓毒症成人(入组前24小时最高体温<38.3°C),比较强制空气加温毯48小时(目标温度较前24小时最低温度高1.5°C)与标准体温管理。主要终点单核细胞HLA-DR表达无差异(692 vs 2,002;p=0.396),CD3/CD28诱导的IFN-γ产生亦无差异(31 vs 69;p=0.678)。干预组28天死亡率更低(18% vs 43%;绝对风险降低25%;95%CI 2-48%),28天无住院日更多(差值2.6天;95%CI 0-11.6)。作者认为未来研究应进一步阐明体温调节对脓毒症免疫及非免疫器官衰竭通路的影响。

要点

  • 纳入标准:机械通气脓毒症成人,脓毒症诊断在入组48小时内,预期机械通气>48小时,入组前24小时最高体温<38.3°C。
  • 干预:强制空气加温毯外加热48小时,目标温度较前24小时记录的最低温度高1.5°C。
  • 主要终点单核细胞HLA-DR表达两组无差异(692 vs 2,002;p=0.396);IFN-γ产生亦无差异(31 vs 69;p=0.678)。
  • 干预组28天死亡率18% vs 对照组43%,绝对风险降低25%(95%CI 2-48%)。
  • 干预组28天无住院日差值2.6天(95%CI 0-11.6)。

适用人群与场景

  • 机械通气的脓毒症成人,脓毒症诊断在入组48小时内,预期需要机械通气大于48小时,入组前24小时内最高体温低于38.3°C。
  • 主要排除标准包括:免疫性疾病、使用免疫抑制药物、任何对治疗性高温敏感的现有疾病(如脑损伤)。

诊断标准与关键阈值

  • 脓毒症诊断在入组48小时内。
  • 入组前24小时内最高体温低于38.3°C。
  • 预期机械通气时间大于48小时。

处置流程与药物剂量

  • 干预组使用强制空气加温毯进行外部加温,持续48小时,目标温度为前24小时记录的最低温度加1.5°C。
  • 对照组接受标准体温管理。

研究设计与关键结果

  • 单中心、前瞻性、开放标签、随机对照先导试验,纳入56例患者。
  • 主要终点单核细胞HLA-DR表达两组无差异(692 vs 2,002;p=0.396)。
  • CD3/CD28诱导的IFN-γ产生两组无差异(31 vs 69;p=0.678)。
  • 干预组28天死亡率18% vs 对照组43%,绝对风险降低25%(95%CI 2-48%)。
  • 干预组28天无住院日差值2.6天(95%CI 0-11.6)。

证据类型、等级与局限

  • 证据类型:单中心、前瞻性、开放标签、随机对照先导试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,未来研究应进一步阐明体温调节对脓毒症免疫及非免疫器官衰竭通路的影响。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To test the hypothesis that forced-air warming of critically ill afebrile sepsis patients improves immune function compared to standard temperature management.

DESIGN: Single-center, prospective, open-label, randomized controlled trial.

SETTING: One thousand two hundred-bed academic medical center.

PATIENTS: Eligible patients were mechanically ventilated septic adults with: 1) a diagnosis of sepsis within 48 hours of enrollment; 2) anticipated need for mechanical ventilation of greater than 48 hours; and 3) a maximum temperature less than 38.3°C within the 24 hours prior to enrollment. Primary exclusion criteria included: immunologic diseases, immune-suppressing medications, and any existing condition sensitive to therapeutic hyperthermia (e.g., brain injury). The primary outcome was monocyte human leukocyte antigen (HLA)-DR expression, with secondary outcomes of CD3/CD28-induced interferon gamma (IFN-γ) production, mortality, and 28-day hospital-free days.

INTERVENTIONS: External warming using a forced-air warming blanket for 48 hours, with a goal temperature 1.5°C above the lowest temperature documented in the previous 24 hours.

MEASUREMENTS AND MAIN RESULTS: We enrolled 56 participants in the study. No differences were observed between the groups in HLA-DR expression (692 vs 2,002; p = 0.396) or IFN-γ production (31 vs 69; p = 0.678). Participants allocated to external warming had lower 28-day mortality (18% vs 43%; absolute risk reduction, 25%; 95% CI, 2-48%) and more 28-day hospital-free days (difference, 2.6 d; 95% CI, 0-11.6).

CONCLUSIONS: Participants randomized to external forced-air warming did not have a difference in HLA-DR expression or IFN-γ production. In this pilot study, however, 28-day mortality was lower in the intervention group. Future research should seek to better elucidate the impact of temperature modulation on immune and nonimmune organ failure pathways in sepsis.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Drewry AM, Mohr NM, Ablordeppey EA, et al. Therapeutic Hyperthermia Is Associated With Improved Survival in Afebrile Critically Ill Patients With Sepsis: A Pilot Randomized Trial. Crit Care Med. 2022. PMID: 35120040. doi:10.1097/CCM.0000000000005470

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。